Phase 3 Trial of RHB-104 as Combination Therapy for Moderate to Severe Crohn’s Is on Track, Review Board Says

Phase 3 Trial of RHB-104 as Combination Therapy for Moderate to Severe Crohn’s Is on Track, Review Board Says
An independent review board has confirmed the preliminary findings of a Phase 3 clinical trial showing that RHB-104 is a safe and effective combination treatment for Crohn’s disease. The Data and Safety Monitoring Board recommended unanimously that the trial continue as planned, according to RHB-104’s developer, RedHill Biopharma. It’s the second time a board has

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *